These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 31055223)
21. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550 [TBL] [Abstract][Full Text] [Related]
22. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397 [TBL] [Abstract][Full Text] [Related]
23. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006 [TBL] [Abstract][Full Text] [Related]
25. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048 [TBL] [Abstract][Full Text] [Related]
26. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum. Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT; Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664 [TBL] [Abstract][Full Text] [Related]
27. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603 [TBL] [Abstract][Full Text] [Related]
28. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968 [TBL] [Abstract][Full Text] [Related]
29. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614 [TBL] [Abstract][Full Text] [Related]
30. Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. Malpas CB; Saling MM; Velakoulis D; Desmond P; O'Brien TJ; J Alzheimers Dis; 2015; 47(4):965-75. PubMed ID: 26401775 [TBL] [Abstract][Full Text] [Related]
31. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479 [TBL] [Abstract][Full Text] [Related]
32. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Susanto TA; Pua EP; Zhou J; J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955 [TBL] [Abstract][Full Text] [Related]
33. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA; Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563 [TBL] [Abstract][Full Text] [Related]
34. Plasma β Huang YM; Ma YH; Gao PY; Wang ZB; Huang LY; Hou JH; Tan L; Yu JT Alzheimers Res Ther; 2023 Apr; 15(1):69. PubMed ID: 37005674 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174 [TBL] [Abstract][Full Text] [Related]
36. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470 [TBL] [Abstract][Full Text] [Related]
37. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]